Five NIH study section members resign over peer review of their grant proposals. Review inequitable for study section members, they say.
FDA orders “limited distribution” for lung cancer drug Iressa.
House approves $210 million for Dept. of Defense cancer research programs.
House Committee on Appropriations approves $28.5 billion for NIH.
House panel investigating NIH handling of tissue specimens.
Trending Stories
- Oncologist Rachna Shroff endows award to outlast her cancer diagnosis
“Because of my health, I have a profound desire to see this endowment come to fruition now” - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Letai: MCEDs are a “great ideal”—alas, the data don’t support widespread use
“Projecting sub-ideal tests across a large population can cause harm,” Letai says, as Galleri cruises toward FDA approval - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”
- Cancer vaccine policy in limbo as CDC keeps canceling advisory meetings









